R Squared’s Cytek Biosciences CTKB Stock Holding History

R Squared’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-280	Closed	-$1.82K	–	583
2024 Q4	$1.82K	Buy	+280	New	+$1.67K	﹤0.01%	1472

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

R Squared's CTKB Position: Q1 2025 in Review

R Squared sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 280 shares — an estimated $1.82K sold.

R Squared first reported a position in CTKB in Q4 2024 and held it in 1 quarter. The position peaked at $1.82K in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

R Squared reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 280 Cytek Biosciences shares in Q1 2025, an estimated $1.82K.
R Squared first reported a position in Cytek Biosciences in Q4 2024 and held it in 1 quarter.
R Squared's Cytek Biosciences position peaked at $1.82K in Q4 2024.
160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.